In addition to the standard annual business, including the election of Directors (see results of voting below) and the appointment of Auditors, shareholders authorized an amendment to the Company's articles to change the corporate name to "Acerus Pharmaceuticals Corporation" and also approved certain amendments to the Company's option plan. Note the corporate name change will be formally announced and implemented at a later date.

Shareholders voted as follows in connection with the election of the directors of the company:

Name Votes For (%) Votes Withheld (%)
Norma Beauchamp 107,055,397 (89.69%) 12,301,271 (10.31%)
Stephen Gregory 107,074,870 (89.71%) 12,281,798 (10.29%)
Ian Ihnatowycz 107,175,597 (89.79%) 12,181,071 (10.21%)
Matthew Pfeffer 107,146,222 (89.77%) 12,210,446 (10.23%)
Rolf Reininghaus 118,931,878 (99.64%) 424,790 (0.36%)
Tom Rossi 107,052,689 (89.69%) 12,303,979 (10.31%)
Jeffrey Sherman 106,551,752 (89.27%) 12,804,916 (10.73%)
Dr. D. Lorne Tyrrell 107,165,394 (89.79%) 12,191,274 (10.21%)

The resolutions authorizing the change in corporate name and amendments to the option plan were approved by 99.67% and 79.76% of votes cast, respectively.

Election of New Director

As a result of the shareholder vote, Ms. Norma Beauchamp joins Trimel's Board of Directors, replacing Mr. John Friedrichsen, who did not stand for re-election to the Board. Ms. Beauchamp is the President and Chief Executive Officer of Cystic Fibrosis Canada, and has held three decades of senior leadership positions in Canada and Germany, including executive positions at Genzyme, Bayer, Sanofi and the Canadian Foundation for Women's Health. She has also been a passionate patient advocate in recent years, working with patient and healthcare organizations to enhance access to care.

Mr. Ian Ihnatowycz, Chair of the Board of Directors of Trimel stated, "On behalf of the Board, we thank Mr. Friedrichsen for his time and dedication to the Company, and we welcome Ms. Beauchamp as a Director. We look forward to leveraging her healthcare experience and leadership in patient advocacy as we continue to execute on the strategic direction of the Company."

About Trimel

Trimel is a Canadian pharmaceutical company focused on the development, manufacture, marketing and distribution of innovative, branded products that improve the patient experience.

Trimel markets ESTRACE® in Canada, a product indicated for the symptomatic relief of menopausal symptoms. NATESTO™, a product utilizing Trimel's licensed nasal gel technology, is the first and only testosterone nasal gel approved and launched in the United States for replacement therapy in adult males diagnosed with hypogonadism, and is currently filed for approval in Canada. The commercial rights to NATESTO™ in the United States and Mexico have been licensed by Trimel to an affiliate of Endo International plc. TEFINA™, a "use as required" nasal testosterone gel, is Trimel's drug development candidate aimed at addressing a significant unmet need for women with female orgasmic disorder.

distributed by